Skip to main content

About Us

ElsaLys Biotech at a glance

ELSALYS BIOTECH is a clinical stage immuno-oncology company that designs and develops a new generation of therapeutic antibodies that target tumors and their immune and/or vascular microenvironment.

By modulating the action of immune cells (immunomodulator antibodies) or by blocking the mechanisms that promote tumor growth (targeted antibodies), ELSALYS BIOTECH intends to offer new options to patients for whom therapy is no longer an option.

To convert these novel targets into drug candidates, the Company relies on a world-class academic network, a team and an R&D platform that encompasses targets sourcing to clinical development and the commercialization of monoclonal antibodies derived from these targets.

Founded in 2013, ELSALYS BIOTECH is located in the heart of the European cluster LYON BIOPOLE. Its founding shareholders are TRANSGENE and SOFIMAC INNOVATION, joined in 2015 by IM EUROPE, a subsidiary of INSTITUT MERIEUX, and CREDIT AGRICOLE CREATION.

23
Average Year Of Experience
5
Candidates Antibodies
20
Academic Partners
1
License Option to a specialist of ophthalmology

Board of Directors

Stéphane Boissel

Non-executive Chairman

Chief Executive Officer of Txcell, Stéphane Boissel has a strong experience in both

Dr Christine Guillen, PharmD

CEO and Co-founder

After holding various positions in the R&D department of LFB, Christine Guillen join

François Miceli

Representative Sofimac Innovation

François Miceli started his career in one of the first French public biot

Dominique Takizawa

Representative IM Europe, a subsidiary of Institut Mérieux

Dominique Takizawa has been Vice President Corpo

Dr Jacques Mizrahi, PhD

Vice President R&D

Jacques Mizrahi joined ElsaLys Biotech in 2014 as a consultant acting Chief Scientif

Dr Eric Quéméneur, PhD

Representative Transgene SA

Eric Quéméneur joined Transgene in September 2014 as Executive Vice President i

Emilie Richard

Representative CA Creation - Observer

Emilie Richard began her career at Société Générale in business agenc

Management team

Dr Christine Guillen, PharmD

CEO and Co-founder

After holding various positions in the R&D department of LFB, Christine Guillen join

Dr Jacques Mizrahi, PhD

Vice President R&D

Jacques Mizrahi joined ElsaLys Biotech in 2014 as a consultant acting Chief Scientif

Liliane Bronstein, MSG

Vice President Finance

Liliane Bronstein brings to ElsaLys Biotech solid experience in executive management

Dr David Liens, MD

Chief Medical Officer

David Liens brings more than 20 years’ experience in the field of drug development an

Dr Catherine Mathis, PharmD

Chief Operating Officer

Catherine Mathis has over 25 years’ experience in clinical research and regulatory

Nathalie Brun, DESCF

Chief Financial Officer

Nathalie Brun has more than 20 years of experience in financial responsibilities in

Founders

Dr Christine Guillen, PharmD

CEO and Co-founder

After holding various positions in the R&D department of LFB, Christine Guillen join

Dr Thierry Menguy, PhD

Head of mAb Development and Production Unit

Co-founder of ELSALYS BIOTECH, Thierry Menguy heads the mAb Dev

Dr Vanessa Duong, PhD

Head of  Preclinical Laboratory

Co-founder of ELSALYS BIOTECH, Vanessa Duong heads the preclinical laborato

Martine Brandt

Office Manager

Co-founder of ELSALYS BIOTECH, Martine Brandt graduated in Business Administration from EM S

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter